SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-19-104426
Filing Date
2019-04-12
Accepted
2019-04-12 06:10:52
Documents
12
Period of Report
2019-06-07

Document Format Files

Seq Description Document Type Size
1 PRE 14A d639522dpre14a.htm PRE 14A 815015
2 GRAPHIC g639522g00d30.jpg GRAPHIC 67656
3 GRAPHIC g639522g01c40.jpg GRAPHIC 76073
4 GRAPHIC g639522g06v41.jpg GRAPHIC 66693
5 GRAPHIC g639522g10v70.jpg GRAPHIC 62477
6 GRAPHIC g639522g14k00.jpg GRAPHIC 31013
7 GRAPHIC g639522g15j69.jpg GRAPHIC 32487
8 GRAPHIC g639522g16a55.jpg GRAPHIC 40109
9 GRAPHIC g639522g18q80.jpg GRAPHIC 37778
10 GRAPHIC g639522g42b45.jpg GRAPHIC 30730
11 GRAPHIC g639522g68m65.jpg GRAPHIC 93641
12 GRAPHIC g639522g87x65.jpg GRAPHIC 131952
  Complete submission text file 0001193125-19-104426.txt   1730024
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS INC (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36070 | Film No.: 19745160
SIC: 2834 Pharmaceutical Preparations